-
Professor Shaji Kumar Details the Breakthrough Application of Talquetamab plus Teclistamab in Relapsed/Refractory Multiple Myeloma with Extramedullary
Extramedullary Disease: The “Solid Ice” of Multiple Myeloma Treatment Multiple myeloma is a hematologic malignancy characterized by the abnormal proliferation of plasma cells in the bone marrow. However, when these…
-
In-depth Analysis of the Background and Core Issues of the EHA Guidelines for Mild-to-Moderate Hemophilia A/B丨2025 EHA Guidelines Meeting
Introduction: Challenging Traditional Cognition, The Systematic Layout of the EHA Guidelines Committee At the beginning of the meeting, Professor Steffen Koschmieder from Aachen, Germany, a member of the EHA Guidelines…
-
EHA-EMN 2025 Guidelines Reshape the Multiple Myeloma Treatment Landscape: Quadruplet Regimens and Immunotherapies Lead a New Era丨EHA 2025
Guideline Update Background: Addressing the Unprecedented Complexity of Treatment Choices At the beginning of the meeting, Professor Peter Sonneveld, President of EHA-EMN, delivered the opening remarks. He pointed out that…
-
ESMO–EHA Release Joint Clinical Practice Guidelines for Peripheral T-Cell Lymphoma, Defining a New Standard in Diagnosis and Treatment丨EHA 2025
Development and Core Framework of the New Guidelines: A Decade of Refinement At the beginning of the meeting, Professor Massimo Federico reviewed the developmental history of PTCL guidelines. He noted…
-
Redefining “Stem Cell”: Professor Sten Eirik Jacobsen Unveils New Mechanisms of Lineage Restriction in Hematopoietic Stem Cells丨EHA 2025
The human hematopoietic system is responsible for vital functions of substance transport and immune defense, with an astonishing cell turnover rate—approximately 90% of all cells are replaced daily by the…
-
Professor Johanna Olweus on Cutting-Edge Breakthroughs and Clinical Translation of TCR-T Therapy | EHA 2025
As a star in the current immunotherapy landscape, Chimeric Antigen Receptor T-Cell (CAR-T) therapy has achieved tremendous success in some hematological tumors. However, its limitations are becoming increasingly apparent. “Currently…
-
Innovative Unsupervised Learning Reshapes AML Subtyping: HARMONY Alliance Study Reveals 17 Novel Biological Subgroups丨EHA 2025
Acute Myeloid Leukemia (AML), as a highly heterogeneous malignancy, presents immense challenges to precise clinical subtyping and treatment due to its complex biological characteristics. Although existing clinical guidelines, such as…
-
From Biological Mechanisms to Targeted Therapy: The Treatment of Immune Thrombocytopenia (ITP) Enters an Era of Precision丨EHA 2025
The 2025 European Hematology Association (EHA) Annual Meeting was grandly held both online and in-person, gathering top experts and scholars from the global hematology community. During the highly anticipated Presidential Symposium, Professor Nicola Cooper, an immune-hematologist from Imperial College London, delivered a keynote speech on “Immune Thrombocytopenia (ITP): From Biology to Targeted Therapy.” She systematically…
Connecting Medical Expertise through Media